NGENNervgen Pharma Corp.$1.88Nov 13 close+16.0%1M+20.1%6M-49.3%

Overview Financials Earnings Peers Projection Compare

Loading company

Every figure taken straight from a company’s own SEC filings, with the checks behind each grade shown — and whatever could not be found named rather than hidden.

Appearance

Product

Screener
Earnings calendar
Watchlists
Portfolios

Browse

Rankings
Free this week
Industries
Curated lists
Fund managers

Company

About
How the grade works
Glossary
Pricing
Contact

Legal

Terms of service
Privacy policy
Disclaimer
Cookie policy

InspectStocks describes businesses using their own reported figures. It is not investment advice and does not recommend buying or selling anything.

Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Nervgen Pharma Corp. (NGEN) latest earnings — what was reported — InspectStocks

NGENNervgen Pharma Corp.$1.88Nov 13 close+16.0%1M+20.1%6M-49.3%

Compare

Overview Financials Earnings Peers Projection Compare

Nervgen Pharma Corp.

NGEN · Nasdaq · Healthcare · Biotechnology

Not rated

Compare

$1.88+16.0%Nov 13 close

Reported results on November 12, 2026; they are not in these figures yet.

Figures through December 31, 2025, from the 40-F filed March 31, 2026

Past performance

1W: +41.4%
1M: +20.1%
3M: +8.4%
6M: -49.3%

The latest quarter we hold for Nervgen Pharma Corp.

From the company’s own 6-K filing.

The quote and the company description come from the 6-K Nervgen Pharma Corp. filed on October 16, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.

Earnings calls

New

The latest call

Fetching

Nervgen Pharma Corp. reported on November 12, 2026. We are fetching the call transcript; its summary follows once the transcript is in.